

1 **running title: An application for aiding COVID-19 diagnosis**

2 **Development and utilization of an intelligent application for aiding COVID-19**

3 **diagnosis**

4 Zirui Meng<sup>1,a</sup>, Minjin Wang<sup>1,a</sup>, Huan Song<sup>2,a</sup>, Shuo Guo<sup>1</sup>, Yanbing Zhou<sup>1</sup>, Weimin Li<sup>3</sup>,

5 Yongzhao Zhou<sup>3</sup>, Mengjiao Li<sup>1</sup>, Xingbo Song<sup>1</sup>, Yi Zhou<sup>1</sup>, Qingfeng Li<sup>4</sup>, Xiaojun Lu<sup>1</sup>,

6 Binwu Ying<sup>1,\*</sup>

7 <sup>1</sup> *Department of Laboratory Medicine, West China Hospital, Sichuan University,*

8 *Chengdu, Sichuan Province, China*

9 <sup>2</sup> *West China Biomedical Big Data Center, West China Hospital, Sichuan University,*

10 *Chengdu, Sichuan Province, China*

11 <sup>3</sup> *Department of Respiratory and critical care medicine, West China Hospital, Sichuan*

12 *University, Chengdu, Sichuan Province, China*

13 <sup>4</sup> *Department of Clinical Laboratory, Public Health Clinical Center of Chengdu,*

14 *Chengdu, Sichuan Province, China.*

15 <sup>a</sup>*Zirui Meng, Minjin Wang, Huan Song. contributed equally to this work.*

16 *Correspondence author: Binwu Ying. No.37 Guoxue Alley, West China Hospital,*

17 *Sichuan University, Chengdu 610041, Sichuan Province, P. R China.*

18 *Tel:86-028-85422751*

19 *Fax:86-028-85422751*

20 *Email:binwuying@126.com*

21

22

23 **Development and utilization of an intelligent application for aiding COVID-19**

24 **diagnosis**

25 **ABSTRACT**

26 **Background:** COVID-19 has been spreading globally since emergence, but the  
27 diagnostic resources are relatively insufficient.

28 **Results:** In order to effectively relieve the resource deficiency of diagnosing  
29 COVID-19, we developed a machine learning-based diagnosis model on basis of  
30 laboratory examinations indicators from a total of 620 samples, and subsequently  
31 implemented it as a *COVID-19 diagnosis aid APP* to facilitate promotion.

32 **Conclusions:** External validation showed satisfiable model prediction performance  
33 (i.e., the positive predictive value and negative predictive value was 86.35% and  
34 84.62%, respectively), which guarantees the promising use of this tool for extensive  
35 screening.

36 **Keywords:** Corona Virus Disease 2019; diagnostic; machine learning; laboratory  
37 testing; Application.

38

39 **BACKGROUND**

40 Since the outbreak of Corona Virus Disease 2019(COVID-19) in Wuhan, in December  
41 2019, the epidemic has spread rapidly all over the world, which consequently brought  
42 great challenges to global public health(1). As of March 14, a total of 142,539 cases  
43 had been confirmed worldwide, with many more requiring tests(2). Currently,  
44 accurate nucleic acid detection plays a pivotal role in diagnosis and prevention of

45 COVID-19, and reverse transcription polymerase chain reaction is the main method  
46 for nucleic acid detection(3). However, it is not feasible to use this time-and  
47 labor-consuming approach for screening a large growing number of suspected patients  
48 and asymptomatic infected patients(4). Rapid and universal screening method is  
49 essential to save medical resources, improve diagnosis efficiency and avoid  
50 cross-infection.

51 Taking advantage of the emerging machine learning technique, which enables analysis  
52 of the existing multidimensional data by applying appropriate algorithms for feature  
53 expression and classification, we have potential to improve the accuracy of diagnosis.  
54 For instance, in a recent study published in Nature, deep learning-based statistical  
55 model was used to improve breast cancer treatment and survival through identifying  
56 breast cancer patients with a high risk of long-term recurrence(5). In this study, we  
57 analyzed a variety of basic laboratory examinations indicators that related to host  
58 reactions to generate a free COVID-19 diagnosis aid APP. Then, the accuracy of this  
59 app was validated in an independent cohort(6).

## 60 **METHODS**

### 61 **Patients and information collection**

62 We have complied with all relevant ethical regulations for work with human subjects  
63 and the studies were approved by the Clinical Trials and Biomedical Ethics  
64 Committee of West China Hospital, Sichuan University. Through the West China  
65 hospital, a regional medical center, we collected the information of confirmed  
66 COVID-19 cases from various regional medical institutions, between 20th December

67 2019 and 10th February 2020. Diagnostic criteria were: RT-PCR of respiratory or  
68 blood samples was positive for SARS-CoV-2 (Severe Acute Respiratory Syndrome  
69 Coronavirus 2) nucleic acid; or viral gene sequencing of respiratory or blood sample  
70 was highly homologous with SARS-CoV-2. Controls were patients collected in the  
71 same site and the same time period, who were free of COVID-19 but had a diagnosis  
72 of viral pneumonia. Results of laboratory examinations on admission were collected  
73 which included age, gender and 35 indicators of whole blood count, coagulation test  
74 and biochemical examination. In addition, the independent validation cohort consisted  
75 of samples collected prospectively from one single medical center, using similar data  
76 collection strategy.

#### 77 **Feature selection and model construction**

78 Factors under consideration are age, sex and indicators of basic laboratory  
79 examinations(see Table 1). Using 70% samples from the derivation cohort (i.e., the  
80 training set), we first performed feature selection using Least Absolute Shrinkage and  
81 Selection Operator (LASSO) to select the valuable indicators of COVID-19. The main  
82 idea of LASSO for feature selection is to construct a first-order penalty function,  
83 which can shrink the regression coefficient (b) of each variable within a certain range,  
84 and eliminate the feature with a coefficient of 0, and finally obtain an optimally  
85 refined model(7). The penalty terms for LASSO are:  $\sum (\text{abs}(b)) \leq t$ . Then these  
86 indicators were used to construct a primitive model by multivariate logistic regression.  
87 The parameters were further adjusted through internal validation (i.e., the other 30%  
88 samples, the testing set) to obtain the optimized final model.

## 89 **Evaluation**

90 In external validation cohort, we compared the predicted results, with the follow-up  
91 results to evaluate the diagnostic validity by positive predictive values, and negative  
92 predictive values. Finally, to facilitate further use in clinic setting, all model  
93 parameters and code were encapsulated as a visual application(APP), *COVID-19*  
94 *Diagnosis Aid APP*.

## 95 **Statistical analysis**

96 Continuous variables are represented by the median (upper and lower quartiles).  
97 Categorical variables are expressed in terms of frequency. LASSO algorithm was used  
98 for feature selection and the model was constructed by multivariate logistic regression.  
99 The diagnostic performance of the model was assessed by AUC. Calibration curves  
100 and Hosmer-Lemeshow test were used to evaluate the degree of overestimation or  
101 underestimation of the model. DCA were used to measure the net clinical benefits.  
102 The LASSO algorithm was performed by “glmnet” package. The logistic regression  
103 model was constructed by “glm” package. All statistical analyses were completed  
104 using R 3.5.0 version.

## 105 **RESULTS**

### 106 **Participants and Clinical Characteristics**

107 A total of 620 samples were included in the derivation cohort, among which 431  
108 samples (211 COVID-19 vs. 220 Control) were in the training set and 189 samples  
109 (91 COVID-19 vs. 98 Control) were in testing set by simple randomization. The  
110 frequency of COVID-19 in the training set (48.96%) was not significantly different

111 from that in the testing set (48.14%). We included 145 samples in the independent  
112 validation cohort.

### 113 **Model development and evaluation**

114 Through Lasso regression screening and Multivariate logistic regression, 9  
115 representative variables (age, Activated Partial Thromboplastin Time, Red Blood Cell  
116 Distribution Width-SD, Uric Acid, Triglyceride, Serum Potassium, Albumin/globulin,  
117 3-Hydroxybutyrate, Serum Calcium) with good identification value were selected and  
118 constructed an optimized diagnostic model(see Figure 1). According to the suggestive  
119 information from the model, among 145 samples that used for validation, 80 samples  
120 were estimated as COVID-19 and 65 samples were considered COVID-19-free.  
121 Compared with the status determined by nucleic acid detection (the golden standard),  
122 we found 69 real COVID-19 samples were correctly identified by the app (69/80,  
123 positive predictive value =86.25%), while 55, out of the 65 COVID-19-free samples,  
124 were confirmed to be negative (55/65, negative predictive value =84.62%). The area  
125 under curve (AUC) of the model were 0.890 and 0.872 in the testing set and  
126 independent validation cohort, respectively(see Figure 2)(8). The calibration curve  
127 performed well and Hosmer-Lemeshow test results P value was much greater than  
128 0.05(see Figure 3). The DCA quantitatively demonstrated high clinical net benefit  
129 over the entire probability threshold(see Figure 4)(9).

### 130 **Construction of application**

131 The model was encapsulated as an APP, *COVID-19 Diagnosis Aid APP*. The risk of  
132 COVID-19 can be obtained by inputting the required indicators into the APP. It will

133 be online in the android store and IOS APP Store soon for facilitating the further  
134 application(see Figure 5).

## 135 **DISCUSSION**

136 According to the latest epidemiological information of the World Health  
137 Organization(WHO), SARS-CoV-2 is spreading worldwide with an intensifying  
138 situation, and many countries including South Korea, Italy, and the United States have  
139 experienced outbreaks(10). Timely diagnosis, isolation and treatment are critical to  
140 control the global spread of COVID-19. However, nucleic acid testing is not always  
141 feasible or fully affordable in all regions. We therefore need more ways to realize the  
142 early and accurate community control and screening of suspicious people. To our  
143 knowledge, this is the first COVID-19 Diagnosis Aid APP based on laboratory tests  
144 for extensive screening. It has good accuracy and stability, which can help medical  
145 institutions to predict patients' situation in advance and accurately invest the limited  
146 healthcare resources, so as to effectively control the spread of the epidemic.

147 Based on the optimized diagnostic model developed in current study, users can obtain  
148 the probability of COVID-19 according to the simple, easily available and reliable  
149 indicators from laboratory examinations. Given satisfiable model prediction  
150 performance (i.e., AUC was 0.872; positive predictive value and negative predictive  
151 value was reach 86.25% and 84.62%, respectively in independent validation cohort),  
152 the application of this app can provide reliable suggestion for further assessment of  
153 the index person, which has potential to reduce anxiety of public, as well as  
154 unnecessary hospital visit and nucleic acid testing.

155 It is undeniable that nucleic acid detection is one of the most reliable standards for the  
156 diagnosis of COVID-19, but we should also be aware of its shortcomings and  
157 deficiencies in practice. Nucleic acid testing requires professional technical platforms  
158 and physicians, and false negative results due to multiple reasons cannot be  
159 completely avoided(11). Instead, laboratory indicators that identified in our study are  
160 accessible, and can be widely used in community hospitals by family doctors to  
161 complete the early stage of suspected population screening.

162 On the other hand, based on the technological revolution brought by the Internet, this  
163 APP software installed on personal mobile can not only help to discover COVID-19  
164 in the most convenient way, but also timely monitor dynamic trends of the prevalence  
165 of the contagious disease through data transmission to the Disease Control Center or  
166 professional medical institution(12, 13). This provides real-time data with predictive  
167 value, which can be reliable basis for more accurate health and epidemic prevention  
168 policies. Furthermore, this APP software is continuously upgradeable, with the  
169 possibility of extended scope of application. For example, we have added the  
170 data acquisition function which enabled the documentation of epidemiological and  
171 clinical features and a personalized reminder for necessary revisits. Also, with futher  
172 implementation of communication function, it is possible to establish a direct  
173 pre-connection between individuals and medical centers, which may benefit patients  
174 by avoiding unnecessary hospital visits or shorten waiting time spend before  
175 admission (14).

176 **CONCLUSION**

177 *COVID-19 Diagnosis Aid APP* can efficiently and accurately calculate the infection  
178 probability through simple and easily-obtained laboratory examination results. It will  
179 promote the screening of a large number of suspected people, save limited medical  
180 resources, optimize the diagnosis process, and it can constantly learn, adapt and  
181 upgrade, which are vital to control the global spread of COVID-19.

182

### 183 **Ethics approval and consent to participate**

184 The protocol of this study was approved by the West China Hospital, Sichuan  
185 University Medical Ethics Committee and conformed to the principles of the  
186 Declaration of Helsinki.

### 187 **The registry number for clinical trial**

188 ChiCTR2000030542

### 189 **Consent for publication**

190 Not applicable

### 191 **Data Availability Statement**

192 The datasets used and analysed during the current study are available from the  
193 corresponding author on reasonable request.

### 194 **Competing interests**

195 The authors declare that they have no competing interests

### 196 **Funding**

197 This study was supported by Science and Technology Department of Sichuan  
198 Province “2020YFS0004” and Science and Technology Project of West China

199 Hospital “HX-2019-nCov-066”

200 **Authors' contributions**

201 Zirui Meng analyzed the data and was a major contributor in writing the manuscript.

202 Minjin Wang designed the APP framework and was a major contributor in writing the

203 manuscript. Huan Song analyzed the data and was a major contributor in writing the

204 manuscript. Shuo Guo analyzed the data. Yanbing Zhou analyzed the data. Weimin Li

205 analyzed patients' medical records. Yongzhao Zhou analyzed patients' medical records.

206 Mengjiao Li collected the data. Xingbo Song verified the performance of the app. Yi

207 Zhou verified the performance of the app. Qingfeng Li collected the data. Xiaojun Lu

208 designed the functions of the app. Binwu Ying proposed research ideas and design

209 research programs. All authors read and approved the final manuscript.

210 **Acknowledgements**

211 The authors thank Beijing Zhongben Tech.co.,Ltd. for their technical contributions to

212 this study.

213 **REFERENCE**

214 1. Z W, JM M. Characteristics of and Important Lessons From the Coronavirus

215 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72□314

216 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020.

217 2. Data as reported by national authorities by 10 AM CET 14 March 2020

218 [Available from:

219 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sit>

220 [ep-54-covid-19.pdf?sfvrsn=dcd46351\\_6](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sit-ep-54-covid-19.pdf?sfvrsn=dcd46351_6).

- 221 3. VM C, O L, M K, R M, A M, DKW C, et al. Detection of 2019 novel coronavirus  
222 (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les  
223 maladies transmissibles = European communicable disease bulletin. 2020;25(3).
- 224 4. T K, SM J, NM L, R K, K H, T M, et al. Communicating the Risk of Death from  
225 Novel Coronavirus Disease (COVID-19). Journal of clinical medicine. 2020;9(2).
- 226 5. OM R, SJ S, JA S, SF C, JL C-J, M C, et al. Dynamics of breast-cancer relapse  
227 reveal late-recurring ER-positive genomic subgroups. Nature.  
228 2019;567(7748):399-404.
- 229 6. F S, N S, F S, Z Z, J S, H L, et al. Emerging Coronavirus 2019-nCoV Pneumonia.  
230 Radiology. 2020:200274.
- 231 7. Tibshirani R. The lasso method for variable selection in the cox model. Stat Med.  
232 1997;16(4):385-95.
- 233 8. Muntner P, Colantonio LD, Cushman M, Goff DC, Jr., Howard G, Howard VJ, et  
234 al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk  
235 equations. JAMA. 2014;311(14):1406-15.
- 236 9. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating  
237 prediction models. Med Decis Making. 2006;26(6):565-74.
- 238 10. S BS, P R, Y S, A M, C C, A S, et al. First cases of coronavirus disease 2019  
239 (COVID-19) in France: surveillance, investigations and control measures, January  
240 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles =  
241 European communicable disease bulletin. 2020;25(6).
- 242 11. T A, Z Y, H H, C Z, C C, W L, et al. Correlation of Chest CT and RT-PCR Testing

243 in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.

244 Radiology. 2020:200642.

245 12. CS W, MR T, J B, TP M-T, K H, D P, et al. Taking connected mobile-health

246 diagnostics of infectious diseases to the field. *Nature*. 2019;566(7745):467-74.

247 13. EV G, A S, ND C. Using the Internet to identify infectious-disease outbreaks. *The*

248 *New England journal of medicine*. 2004;351(24):2558-9.

249 14. JT W, K L, GM L. Nowcasting and forecasting the potential domestic and

250 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a

251 modelling study. *Lancet (London, England)*. 2020.

252

253

254

255

256

257

258

259

260

261

262

263

264

265 **Table 1. Candidate of the model.**

	Derivation cohort		Validation cohort	
	Control	COVID-19	Control	COVID-19
SEX	female(27.41%)	female(31.07%)	female(31.21%)	female(30.56%)
AGE	68.5(77,81)	46(55,73)	66(76,84)	48(58,67)
PT	11(11.75,13.25)	10.7(11.8 ,13.4)	11.1(12,13.7)	11(11.7,12.7)
INR	0.95(1.06,1.15)	0.94(1.04,1.16)	0.97(1.06,1.20)	0.96(1.02,1.12)
APTT	28.18(29.75,35.68)	25.60(27.90,31.40)	27.38(30.10,35.43)	25.68(28.25,32.20)
TT	17.10(18.00,19.13)	16.40(17.20,18.10)	17.20(18.20,19.60)	16.98(17.90,19.10)
RBC	3.13(3.76,4.13)	3.66(4.25,4.76)	3.10(3.68,4.15)	3.47(3.98,4.44)
HGB	93.25(110.50,126.50)	111.00(129.00,148.00)	91.75(110.00,123.00)	103.00(119.00,135.00)
HCT	0.29(0.35,0.39)	0.35(0.38,0.44)	0.29(0.34,0.38)	0.32(0.36,0.40)
MCV	88.13(92.20,96.30)	88.50(91.50,95.00)	88.90(93.25,97.20)	88.40(91.65,95.53)
MCH	29.00(29.90,31.20)	28.90(30.70,32.10)	28.90(30.00,31.30)	29.10(0.40,31.70)
MCHC	317.00(325.00,335.25)	320.00(334.00,345.00)	314.00(324.00,332.00)	318.00(328.00,339.00)
RDW-SD	44.58(47.45,51.13)	41.90(44.50,49.80)	45.08(49.20,54.10)	42.65(46.20,50.25)
RDW-CV	13.40(14.10,15.33)	12.80(13.60,15.10)	13.70(14.60,15.90)	13.18(13.90,14.90)
PLT	135.75(186.00,230.75)	107.00(147.00,202.00)	130.00(203.50,276.25)	126.75(203.50,277.75)
WBC	5.73(7.39,9.02)	6.52(9.59,14.89)	5.87(8.02,11.04)	5.22(7.42,11.09)
TBIL	6.20(9.75,15.18)	8.50(12.20,17.50)	6.90(9.65,14.48)	7.60(10.30,14.40)
DBIL	2.48(3.80,6.28)	3.70(5.70,7.50)	2.90(4.40,7.13)	3.30(4.60,7.23)

IBIL	3.78(4.95,6.98)	4.00(6.10,9.10)	3.30(4.60,7.10)	3.40(5.10,7.50)
ALT	12.00(19.00,30.25)	18.00(27.00,55.00)	13.00(21.00,37.00)	19.00(31.50,57.00)
AST	18.75(23.00, 36.00)	22.00(36.00,68.00)	19.00(25.50,39.25)	21.00(33.00,55.00)
TP	53.90(58.85,68.13)	60.80(65.90,72.10)	56.48(62.05,68.53)	55.90(60.85,66.33)
ALB	32.70(36.10,41.65)	30.70 (34.10,39.00)	31.30(34.75,38.53)	29.90(32.95,37.23)
GLB	19.43(23.80,28.45)	27.50(31.80,35.90)	22.50(26.50,30.93)	23.38(27.00,31.60)
A/G	1.33(1.51,1.91)	0.90(1.11,1.32)	1.11(1.35,1.61)	1.03(1.22,1.46)
GLU	4.92(6.00,7.64)	6.31(7.33,9.67)	5.49(7.20,9.40)	5.10(6.24,8.40)
UREA	4.60(6.05,8.25)	4.20(6.20,10.40)	4.58(6.69,9.43)	3.40(4.73,7.00)
CREA	50.50(60.50,103.50)	60.00(75.00,94.00)	50.00(65.50,90.00)	51.00(61.00,77.00)
eGFR	60.87(89.49,97.73)	66.14(96.38,104.66)	63.45(86.14,100.87)	87.21(101.88,112.20)
Cys-C	0.90(1.06,1.69)	0.86(1.06,1.42)	0.92(1.16,1.68)	0.82(0.96,1.23)
URIC	154.75(219.00,291.25)	181.00(281.00,366.00)	133.75(200.00,287.25)	138.00(192.00,281.00)
TG	0.71(0.93,1.23)	0.98(1.17,1.80)	0.76(1.03,1.34)	0.94(1.30,1.82)
CK	41.75(56.00,86.75)	39.00(87.00,204.00)	29.00(49.50,84.25)	36.00(62.00,125.25)
NA	135.30(139.20,141.83)	131.40(135.50,139.10)	135.95(139.70,142.60)	135.80(139.15,141.70)
K	3.72(4.08,4.38)	3.32(3.76,4.09)	3.73(4.08,4.51)	3.57(3.96,4.38)
β-HBA	0.07(0.12,0.23)	0.08(0.23,0.38)	0.07(0.11,0.22)	0.06(0.12,0.30)
CA	2.06(2.15,2.21)	2.01(2.11,2.23)	2.02(2.14,2.24)	1.97(2.07,2.17)

266 Data are presented as n (%) for categorical variables and as median (interquartile range) for continuous variables.

267 PT, prothrombin time; INR, International Normalized Ratio; APTT, activated partial thromboplastin time; TT,

268 thromboplastin time; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, Mean Corpuscular Volume;

269 MCH, Mean Corpuscular Hemoglobin; MCHC, Mean Corpuscular Hemoglobin Concentration; RDW-SD, Red  
270 Blood Cell Distribution Width-SD; RDW-CV, Red Blood Cell Distribution Width-CV; PLT, Platelets; WBC, white  
271 blood cell; TBIL, total Bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; ALT, alanine aminotransferase;  
272 AST, glutamic oxaloacetic transaminase; TP, Total Protein; Alb, albumin; ALB, albumin; GLB, globulin ratio; A/G,  
273 albumin globulin ratio; GLU, glucose; CREA, serum; eGFR, estimated Glomerular Filtration Rate; Cys-C, cystatin;  
274 URIC, uric acid; TG, Triglyceride; CHOL, cholesterol; CK, creatine kinase; NA, serum sodium; K, Serum  
275 Potassium;  $\beta$ -HBA, 3-Hydroxybutyrate; CA, Serum Calcium;

276

## 277 **Figure legends**

278 **Figure.1(a) Coefficient diagram of LASSO variables.** Each curve in the figure  
279 represents the trajectory of the coefficient of an independent variable. The ordinate is  
280 the value of the coefficient. The lower abscissa,  $\lambda$ , is the parameter that controls the  
281 severity of the penalty. The upper abscissa is the number of non-zero coefficients in  
282 the model under the penalty parameter. **(b) Adjustment parameters in the LASSO**  
283 **model.** The lambda is screened by 10 folds cross-validation. A dashed vertical line is  
284 drawn at one standard error (1-SE standard) of the minimum and minimum standards.  
285 Lambda.1se corresponds to a model with good performance but the fewest number of  
286 arguments.


287 **Figure 2. Receiver operator characteristic curve.** The AUC were 0.890 and 0.872  
288 in derivation and validation cohort respectively.

289 **Figure 3. Calibration curves.** The 45° shaded line represents the ideal prediction and  
290 the prediction probability is consistent with the actual observation probability. The


291 Solid line represents the actual prediction of the model. The stapled histogram on the  
292 bottom line represents the distribution of patients' predicted probability. Abbreviations:  
293 Dxy = Somer's D rank correlation, R2 = Nagelkerke-Cox-Snell-Maddala- Magee  
294 R-squared index, D = Discrimination index, U = Unreliability index, Q = Quality  
295 index, Emax = maximum absolute difference in predicted and calibrated propabilities,  
296 S:z = Spiegelhalter Z-Test, S:p = two-tailed p-value of the Spiegelhalter Z-test.

297 **Figure 4. Decision curve analysis.** The horizontal axis is the threshold probability of  
298 occurrence of COVID-19. The vertical axis shows the clinical benefits that patients  
299 may gain or lose using the APP. Dotted line: prediction model. Solid line: all patients  
300 were COVID-19 . Horizontal line: all patients were not COVID-19.


301 **Figure 5. APP schematic.** The model can show the probability of COVID-19 after  
302 inputing the corresponding index into the the APP.





a



b









## West China Hospital COVID-19 Screening Assistant

Fill in each assay index in detail, get probability after submitting

[Modify clinical symptoms](#)

Please fill in the data source of this laboratory test

Check the hospital Please enter hospital name

Check date Please select the inspection date >

Contact Way Please enter contact way

[Fill in all test indicators](#)



[Personal data](#)

[My case](#)

[Feedback](#)

[Contact us](#)

[Setting](#)


19

ptoms.

me

>

ay



Check the hospital Please enter hospital name

Check date Please select the inspection date >

Contact Way Please enter contact way

Gender Please select gender >

age(AGE) Please enter age

Red Blood Cell Distribution Width-SD(RDW-SD) Please enter the value FL

Activated Partial Thromboplastin Time(APTT) Please enter the value S

Triglyceride(TG) Please enter the value mmol/L

Albumin/globulin(A/G) Please enter the value

Uric Acid(URIC) Please enter the value umol/L

Serum Potassium(K) Please enter the value mmol/L

Serum Calcium(CA) Please enter the value mmol/L



Diagnostic probability



Probability value


86.20%

According to your test results, you are at higher risk of COVID-19. Do not be panic. Please observe your physical condition closely. It is recommended to wear a mask and consult a local doctor.

[Back Homepage](#)



If you have any questions, please send them to the following mailbox  
[Huaxi\\_Coronavirus@126.com](mailto:Huaxi_Coronavirus@126.com)



2020-03-18 09:36:01 Probability value:86.2%

Check the hospital westChina

Check date 2020-03-18

Contact Way 15780917878

Gender 女

Age 23

[View details](#)

2020-03-17 15:29:58 Probability value:94.15%

Check the hospital WestChina

Check date 2020-03-07

Contact Way 15680916878

Gender 女

Age 23

[View details](#)

2020-03-17 11:17:36 Probability value:99.71%

Check the hospital West China

Check date 2020-03-12

Contact Way 15680916878

Gender 女